What checks must pharmacies make before supplying weight-loss medicines?

What does the demand data show?

Start with the finding that generated trade coverage in July 2026. The digital healthcare provider Zava surveyed just over 1,000 British weight-loss medicine users. It found that 21 per cent — about one in five — held no prescription from a healthcare professional for the medicine they were taking. The same survey recorded around one in six buying doses through general e-commerce platforms, and just under 12 per cent sourcing them through social media platforms or influencers.

A separate Atomik Research survey of 2,000 UK adults put the figures higher among injection users. 41 per cent had sourced pens online without a prescription, and 35 per cent had obtained them through a family member or friend. Sharing a prescription-only medicine between friends is a supply — most participants would simply not recognise it as one. That is much of why the practice persists.

The academic picture matches the commercial polling. Research led by UCL, published in early 2026, was based on a representative survey of 5,260 adults. It estimated that 1.6 million people in Great Britain used weight-loss drugs in the year to early 2025, with a further 3.3 million interested in starting. It also found about one in seven users taking products not licensed for weight loss at all, among them the off-label diabetes formulations. The researchers' own framing carries the operational point. Substantial numbers of people are taking these drugs outside medical supervision, and NHS prescribing data captures only a fraction of the picture.

London shows the market's shape in a single contrast, recorded in a London Assembly Health Committee report in March 2026. About half a million Londoners were potentially eligible. Around 3,000 were receiving the medicines on the NHS as of late 2025, and tens of thousands were estimated to be buying privately. The committee called that disparity a two-tier system. The same report gathered the behaviours any online provider must design against. They include reports of people misstating their weight to obtain supplies from online pharmacies, and purchases made through social media and beauty salons.

Read together, the surveys describe the market. A substantial minority of people presenting to a service have already obtained, or could readily obtain, the same medicine with no checks whatever. That is the context in which a provider's verification either carries meaning or does not. Our market analysis covers how demand reached this position. This article concerns the duties that follow from it.

What is the regulatory temperature?

Elevated, and rising over a two-year period. The GPhC strengthened its guidance for online pharmacy services in February 2025, ending questionnaire-only prescribing for high-risk categories — with weight-loss medicines named prominently. The full framework is examined in our remote prescribing article. Its central requirement is independent verification rather than reliance on self-report.

The MHRA has meanwhile been assembling the clinical risk file. In June 2025 it warned that weight-loss medicines may reduce the effectiveness of oral contraceptives and that effects in pregnancy are not established. It also warned that GLP-1 medicines may be associated with pancreatitis. Clinicians in acute medicine have reported serious complications among people who bought the drugs online. NHS England's medical director had already described the medicines as being used inappropriately in 2024. In evidence gathered by the London Assembly, both the MHRA and the GPhC are recorded as concerned about certain providers. The concern: internal prescribing targets for weight-loss medicines, and failure to identify patients for whom GLP-1 treatment is inappropriate. That is about as close as regulators ordinarily come to naming a business model.

The enforcement logic follows the pattern tracked across GPhC enforcement generally. Where a category combines high demand, high margin and documented harm, regulatory attention concentrates on whether providers' checks are genuine. A weight-loss service's verification records are therefore clinical governance, not administration. They determine which side of the regulators' analysis the provider sits on.

The prescribing-targets concern identifies a structural failure, not an individual bad actor. A target need not be a quota on a whiteboard. It can be a conversion dashboard visible to the clinical team, or a bonus geared to approvals. It can be a funnel review treating refusals as leakage, or simply a rota sized so that declining takes longer than approving. The safeguard is prescriber independence made structural. That means prescribers paid without reference to approval rates. It means refusal rates reviewed as a quality signal, not a performance concern. And it means a governance line of the kind mapped in our clinic-plus-pharmacy guide, where the clinical decision and the commercial interest are visibly separated. If a regulator reconstructed the incentive structure from payroll and dashboards, nothing should be found that leans on the prescriber.

What did the GPhC publish in 2026?

Two documents materially raised the stakes during 2026. Anyone operating in this category should read both.

On 24 April 2026 the regulator published a themed review, Weight management medicines and services, a review of GPhC inspections and concerns. It draws on inspection reports and concerns received between January 2024 and December 2025. Its findings describe the failure pattern precisely: weaknesses in risk assessments and clinical governance arrangements, incomplete or insufficient patient consultation records, inconsistent processes for independently verifying weight and BMI, poor communication, and limited arrangements for ongoing clinical follow up and customer support.

The review sets out six recommended actions. Together they are the most useful specification currently available for anyone building or auditing a service.

Two features of that list deserve emphasis, because they extend beyond the verification question. Due diligence on third party prescribing services makes the pharmacy responsible for the prescriber arrangements it relies on. That bears directly on the contracted-prescriber model most services adopt. And specific consideration of vulnerable groups including individuals with eating disorders is the clearest statement yet on screening. Eligibility screening must actively identify people for whom treatment is inappropriate, not simply confirm that a threshold was met.

The regulator's Chief Pharmacy Officer framed the review as being about more than compliance. In that framing, strengthened governance, enhanced clinical safeguards and improved transparency are what make a service safe, reliable and person-centred. A service reading the six actions as an audit checklist has taken the useful part. A service reading them as a design specification has taken the point.

A third development completes the picture. On 18 June 2026 the GPhC joined the MHRA and the Advertising Standards Authority in a statement: prescription-only medicines may not be advertised to the public. The warning extends to pipeline medicines that do not yet hold a licence. The themed review had already identified advertising of weight management services and medicines as a substantial share of the concerns received — including reports of pharmacies paying influencers to promote them. So the advertising boundary is now enforced by three bodies at once in this category. Its interaction with patient testimonials is examined in our reviews article.

What are the six verification gates?

A defensible weight-loss service verifies six things and can evidence its reasoning for each. The table maps the framework. The discussion that follows takes the gates in turn.

Gate 2 attracts the greatest market pressure and gets its own section below. Gate 3 carries the counselling content the MHRA's warnings now define. A service prescribing to a woman of childbearing age without documenting the contraception discussion is disregarding a named regulatory warning. Eating disorder screening is where a weight-loss service's ethics are genuinely tested. The applicants the screen exists to protect are the ones most motivated to pass it.

In practice this means screening built around patterns, not individual answers. Watch for applications at or near the eligibility threshold, and weight histories that do not reconcile with the timeline offered. Watch for rapid reapplication after refusal, and requests whose urgency is out of proportion to the clinical picture. It also requires a defined escalation path, a named clinician reviewing flags, authority to decline without commercial override, and signposting to appropriate support delivered with care. The person generating a flag is a patient, not a fraud case.

Gate 4 addresses the behaviour the surveys identified. In a market where a third of users obtain supply through friends and family, the applicant may already be taking the medicine. Adding a legitimate supply on top of an informal one is a harm checks can prevent. Gate 5 is the pharmacy's own contribution to the integrity of the supply chain. Gate 6 separates treatment from retail. The demand data shows what unsupervised use produces at population scale, and a provider whose involvement ends at dispatch has built supervised access to an unsupervised experience.

What is the self-report problem?

In practice, that can take several forms. Video consultation with the measurement observed or credibly assessed. Corroboration against GP records or a summary care record, where consent and access permit. Photographic evidence — though only within a framework that accounts for manipulation and, more importantly, for the dignity of the person supplying it. And consistency checks over time, because a returning patient whose reported weight and dose response fail to reconcile is telling you something.

None of these is enough on its own. But the standard is not perfection. It is a process the provider can defend as genuinely independent of the applicant's self-interest, applied consistently, and recorded.

How do the gates map onto the patient journey?

A framework only becomes usable once it is sequenced. Here is where each gate sits in an operating service.

At application. Identity and age verification run first, before clinical data is collected — there is no point assessing a person who may not exist. Duplication checks run against the provider's own records at the same moment.

At consultation. Independent measurement happens here, whether video-based or record-corroborated. Alongside it sit the structured suitability assessment, the pregnancy and contraception discussion for applicable patients, the supply-history question asked plainly, and eating disorder screening integrated throughout rather than bolted on. The prescriber's decision is recorded with reasons in either direction.

At first supply. Counselling that covers the MHRA-flagged risks in language the patient will remember. It covers the side effects that warrant stopping, the titration schedule and why advancing it is dangerous, and how to contact the service between reviews.

At every repeat. A review genuinely capable of stopping treatment: weight and response reconciled against the record, side effects checked, and the interval enforced. A repeat issued early without explanation is a dose unaccounted for.

Continuously. The monitoring machinery: recalls that fire when reviews are missed. And aggregate governance that lets the superintendent see refusal rates, flag patterns and interval breaches across the service, not one file at a time.

Sequenced this way, the gates cost the honest patient a few minutes and cost the dishonest application everything. That is the correct asymmetry. If verification feels burdensome for legitimate patients, the service has usually ordered the gates wrongly, not built too many of them.

What does the oral era change?

On 6 July 2026 the oral formulation of Wegovy went on sale in UK pharmacies through private weight-management programmes, following MHRA approval in June. The sector saw the demand effect coming. A survey of 310 pharmacy owners published the same week recorded about three quarters expecting a surge in demand. 49 per cent had already observed increased patient queries. The most relevant finding sits alongside those: 97 per cent of surveyed pharmacies were concerned the tablet would increase fake or unlicensed weight-loss products on the black market.

That concern is well founded on first principles. A tablet is more convincingly counterfeited than an injection pen. It is more readily split from a pack and sold in small quantities, and more easily shared. And it passes more easily through the informal networks the surveys already show supplying a third of users.

For a legitimate provider, the oral era therefore raises the premium on two gates. Supply integrity matters more, because counterfeit pressure flows toward whatever is most readily faked. The provenance of stock becomes a patient safety fact, and one patients will increasingly ask about. The patient-source conversation matters more too. An applicant starting with a service may be switching from a product of unknown origin, which materially alters the clinical picture. A service that asks, without judgement, what a person has already been taking and where it came from is doing harm reduction the black market cannot.

What does declining well involve?

A verification framework only carries meaning if it produces refusals. Refusals are clinical work, not lost revenue. Decline with a reason the patient can understand. Record the decision with the care you would apply to a supply: what was checked, what failed or flagged, and what was advised. And redirect to the GP or an appropriate service, rather than leaving the applicant to approach the next provider with weaker checks.

Treat circumvention attempts as information, not just obstruction. Implausible figures, resubmissions under variant details and pressure to skip steps mean fraud in some cases, desperation in others, and occasionally an eating disorder presenting as determination. In each case the record should hold the observation, and the superintendent's governance should see it in aggregate. The providers regulators cited for prescribing targets had optimised for approval. A defensible service is one whose refusals are documented, humane and frequent enough to be credible.

What evidence pack does scrutiny request?

Use the following as a self-audit, in the spirit of our inspection guide. These are the artefacts an inspector — or a coroner — would request from a weight-loss service.

Start with the service specification and standard operating procedures — current, and specific to weight-loss supply rather than adapted boilerplate. Then the verification method statement: how height and weight are independently determined, with sampled records showing that it happens. Then the prescriber governance file: who prescribes, their independence from commercial outcomes, and how refusals are reviewed.

Add a run of patient journeys end to end, from application to review, including at least one refusal and one stopped treatment. A service with no examples of either is exhibiting a symptom. Add the duplication and multi-provider check design. Procurement records tracing stock to licensed wholesalers. The counselling content covering the contraception and pancreatitis warnings, with evidence it was delivered rather than linked. The recall log showing that missed reviews were pursued. And the aggregate governance pack — refusal rates, flag themes and incident learning — showing that someone senior examines the whole.

A provider able to produce that pack within an afternoon is not merely compliant. It also holds the strongest marketing claim available in this category: being demonstrably unlike the market the surveys describe.

Key takeaways

FAQs